Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Respiratory Syncytial Virus Infection: early-phase trial registry
1 of 5 indexed Respiratory Syncytial Virus Infection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Respiratory Syncytial Virus Infection: 5 US clinical trials tracked, 1 recruiting.
Respiratory Syncytial Virus Infection is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 1 of these trials.
Enrollment posture brief
Registry condition respiratory-syncytial-virus-infection
OPEN 1 | RECR 20% | LATE 1 | EARLY 3 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Respiratory Syncytial Virus Infection lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Respiratory Syncytial Virus Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Respiratory Syncytial Virus Infection is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Respiratory Syncytial Virus Infection research.
Gilead Sciences accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Respiratory Syncytial Virus Infection enrolment sits around 100 participants.
Median target enrolment is 100 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Respiratory Syncytial Virus Infection research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Fred Hutchinson Cancer Center
NCT06817889
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06551506
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
Merck Sharp & Dohme
NCT04767373
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
University of Rochester
NCT06424795
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Gilead Sciences
NCT02254421
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Respiratory Syncytial Virus Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Respiratory Syncytial Virus Infection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Respiratory Syncytial Virus Infection page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Respiratory Syncytial Virus Infection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Gilead Sciences sponsors the most Respiratory Syncytial Virus Infection trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Respiratory Syncytial Virus Infection condition card totals 5 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.